7 research outputs found
Differential drug effects on cellular tyrosine phosphorylation.
<p>Cells were treated for 30 min with bafetinib (800 nM), bosutinib (400 nM), dasatinib (100 nM) and nilotinib (4 µM), which are concentrations equivalent to reported maximum patient plasma concentrations, and DMSO control. Effects of individual drugs were determined by immunoblot analysis for BCR-ABL (α-ABL) and total phosphotyrosine (α-pY). Actin served as loading control. <b>A</b>. Dasatinib had the strongest impact on cellular tyrosine phosphorylation in BV-173 cells while the effects of bafetinib, nilotinib and particularly bosutinib were less pronounced. <b>B</b>. Dasatinib completely abolished cellular tyrosine phosphorylation in Z-119 cells. BCR-ABL levels were not appreciably affected, but it’s phosphorylation (marked by arrow) was inhibited by the drugs in either cell line.</p
Graphical representation of binding specificity assessment.
<p>Using the example of dasatinib and BV-173 cells, the average spectral counts obtained from chemical proteomics were compared with the respective competition experiments in the presence of 20 µM free drug in a double-logarithmic plot. Specific ( ♦) and non-specific (◊) binders were identified by definition of a specificity gate (grey area) with a ratio threshold of 2 and a minimum average spectral count of 10. For proteins that were not identified in the competition experiment, the minimum average spectral count was lowered to 1. </p
Hybrid drug-protein/protein-protein interaction networks of specific drug binding proteins.
<p>Individual cellular target profiles of nilotinib (green), dasatinib (red), bosutinib (yellow) and bafetinib (blue) were intersected with each other and overlaid with PPI data from public databases. Protein kinases and the oxidoreductase NQO2, as a validated target of nilotinib and to lesser extent of bafetinib, were considered to be direct drug binders (solid lines) and color-coded according to the drug they were interacting with. Shared kinase targets display a split color code. All other non-kinase proteins were assumed to be indirect binders (dashed lines) and displayed in grey. The analysis reveals distinct protein complexes, which are enriched by particular drugs and which are highlighted with the respectively colored background. <b>A</b>. Z-119 drug-protein interaction network. <b>B</b>. BV-173 drug-protein interaction network.</p
Schematic outline of the integrated chemical proteomics and computational biology strategy.
<p><b>A</b>. Drug-protein interaction networks are generated by chemical proteomics while the protein-protein interaction (PPI) network is derived from public databases and modified to represent the specific disease. The interaction networks are correlated through a random walk approach across the PPI network using proteins from the drug-protein network as entry points. The resulting correlation scores are subsequently validated by cell proliferation assays. <b>B</b>. Chemical structures of the four second-generation BCR-ABL tyrosine kinase inhibitors dasatinib (Sprycel, BMS-354825), nilotinib (<i>Tasigna</i>, AMN107), bosutinib (SKI-606) and bafetinib (INNO-406, NS-187) as well as their coupleable analogues c-dasatinib, c-nilotinib, c-bosutinib and c-bafetinib that were used for immobilization and subsequent chemical proteomics experiments.</p
presentation_1_Extracellular Purine Metabolism Is the Switchboard of Immunosuppressive Macrophages and a Novel Target to Treat Diseases With Macrophage Imbalances.PDF
<p>If misregulated, macrophage (Mϕ)–T cell interactions can drive chronic inflammation thereby causing diseases, such as rheumatoid arthritis (RA). We report that in a proinflammatory environment, granulocyte-Mϕ (GM-CSF)- and Mϕ colony-stimulating factor (M-CSF)-dependent Mϕs have dichotomous effects on T cell activity. While GM-CSF-dependent Mϕs show a highly stimulatory activity typical for M1 Mϕs, M-CSF-dependent Mϕs, marked by folate receptor β (FRβ), adopt an immunosuppressive M2 phenotype. We find the latter to be caused by the purinergic pathway that directs release of extracellular ATP and its conversion to immunosuppressive adenosine by co-expressed CD39 and CD73. Since we observed a misbalance between immunosuppressive and immunostimulatory Mϕs in human and murine arthritic joints, we devised a new strategy for RA treatment based on targeted delivery of a novel methotrexate (MTX) formulation to the immunosuppressive FRβ<sup>+</sup>CD39<sup>+</sup>CD73<sup>+</sup> Mϕs, which boosts adenosine production and curtails the dominance of proinflammatory Mϕs. In contrast to untargeted MTX, this approach leads to potent alleviation of inflammation in the murine arthritis model. In conclusion, we define the Mϕ extracellular purine metabolism as a novel checkpoint in Mϕ cell fate decision-making and an attractive target to control pathological Mϕs in immune-mediated diseases.</p
video_1_Extracellular Purine Metabolism Is the Switchboard of Immunosuppressive Macrophages and a Novel Target to Treat Diseases With Macrophage Imbalances.mov
<p>If misregulated, macrophage (Mϕ)–T cell interactions can drive chronic inflammation thereby causing diseases, such as rheumatoid arthritis (RA). We report that in a proinflammatory environment, granulocyte-Mϕ (GM-CSF)- and Mϕ colony-stimulating factor (M-CSF)-dependent Mϕs have dichotomous effects on T cell activity. While GM-CSF-dependent Mϕs show a highly stimulatory activity typical for M1 Mϕs, M-CSF-dependent Mϕs, marked by folate receptor β (FRβ), adopt an immunosuppressive M2 phenotype. We find the latter to be caused by the purinergic pathway that directs release of extracellular ATP and its conversion to immunosuppressive adenosine by co-expressed CD39 and CD73. Since we observed a misbalance between immunosuppressive and immunostimulatory Mϕs in human and murine arthritic joints, we devised a new strategy for RA treatment based on targeted delivery of a novel methotrexate (MTX) formulation to the immunosuppressive FRβ<sup>+</sup>CD39<sup>+</sup>CD73<sup>+</sup> Mϕs, which boosts adenosine production and curtails the dominance of proinflammatory Mϕs. In contrast to untargeted MTX, this approach leads to potent alleviation of inflammation in the murine arthritis model. In conclusion, we define the Mϕ extracellular purine metabolism as a novel checkpoint in Mϕ cell fate decision-making and an attractive target to control pathological Mϕs in immune-mediated diseases.</p
video_2_Extracellular Purine Metabolism Is the Switchboard of Immunosuppressive Macrophages and a Novel Target to Treat Diseases With Macrophage Imbalances.mov
<p>If misregulated, macrophage (Mϕ)–T cell interactions can drive chronic inflammation thereby causing diseases, such as rheumatoid arthritis (RA). We report that in a proinflammatory environment, granulocyte-Mϕ (GM-CSF)- and Mϕ colony-stimulating factor (M-CSF)-dependent Mϕs have dichotomous effects on T cell activity. While GM-CSF-dependent Mϕs show a highly stimulatory activity typical for M1 Mϕs, M-CSF-dependent Mϕs, marked by folate receptor β (FRβ), adopt an immunosuppressive M2 phenotype. We find the latter to be caused by the purinergic pathway that directs release of extracellular ATP and its conversion to immunosuppressive adenosine by co-expressed CD39 and CD73. Since we observed a misbalance between immunosuppressive and immunostimulatory Mϕs in human and murine arthritic joints, we devised a new strategy for RA treatment based on targeted delivery of a novel methotrexate (MTX) formulation to the immunosuppressive FRβ<sup>+</sup>CD39<sup>+</sup>CD73<sup>+</sup> Mϕs, which boosts adenosine production and curtails the dominance of proinflammatory Mϕs. In contrast to untargeted MTX, this approach leads to potent alleviation of inflammation in the murine arthritis model. In conclusion, we define the Mϕ extracellular purine metabolism as a novel checkpoint in Mϕ cell fate decision-making and an attractive target to control pathological Mϕs in immune-mediated diseases.</p